Why is Micro-Cap Aptevo stock disorders higher on Wednesday? – Aptevo Therapeutics (Nasdaq: APVO)

Aptevo Therapeutics Inc APVO The shares rise on Wednesday. According to data from Benzinga Pro, the share is higher with a strong volume of 81.8 million compared to the average volume of 275.3k. What happened: Aptevo revealed new clinical data from the current phase 1b/2 Rainier study for evaluation of mipletamig, the first-in-class CD123 x […]

Exclusive: GT Biopharma promotes a recurrent blood cancer therapy study to cohort 2 after promising early safety results – GT Biopharma (Nasdaq: GTBP)

GT Biopharma, Inc. GTBP announced on Monday that it successfully completed the dosage in cohort 1 and started dosing in cohort 2 of his phase 1 dose of escalation study for GTB-3650. The therapy is a trike-therapeutic targeting of the second generation, refunded or refractory CD33-to expression hematological malignancies. GT Biopharma specializes in immuno-oncology therapies […]